Human menopausal gonadotropin (hMG) is a type of fertility drug that
contains a mixture of follicle-stimulating hormone (FSH) and luteinizing hormone
(LH) extracted from the urine of postmenopausal women. It is used to stimulate
the ovaries to produce multiple eggs in women who have ovulation problems or who
are undergoing assisted reproductive technology (ART) procedures. hMG can also
be used to treat male infertility caused by low sperm count or poor sperm
quality.
One of the leading companies that produce hMG is Ferring Pharmaceuticals, a
global biopharmaceutical company headquartered in Switzerland. Ferring
Pharmaceuticals has been developing and marketing hMG products since 1950, and
has a strong presence in the field of reproductive medicine and maternal health.
Ferring Pharmaceuticals offers several hMG products under different brand names,
such as Menopur, Bravelle, Repronex, and Menogon. These products differ in their
composition, dosage, administration, and indications, depending on the needs and
preferences of the patients and doctors.
hMG is a highly effective and safe treatment option for many couples who
struggle with infertility. However, it also has some potential risks and side
effects, such as ovarian hyperstimulation syndrome (OHSS), multiple pregnancy,
ectopic pregnancy, miscarriage, allergic reactions, and injection site
reactions. Therefore, hMG should only be used under the supervision of a
qualified medical professional who can monitor the patient's response and adjust
the treatment accordingly. hMG is also a costly medication that may not be
covered by insurance plans, so patients should consult their health care
providers and pharmacists before starting the treatment.